The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.

@article{Han2002ThePS,
  title={The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.},
  author={Shiuw H. Han and John M. H. de Klerk and Suzy Tan and Alfred D. van het Schip and Bert H Derksen and Aalt van Dijk and Cas L. J. J. Kruitwagen and Geert H. Blijham and Peter P. van Rijk and Bernard A Zonnenberg},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2002},
  volume={43 9},
  pages={1150-6}
}
UNLABELLED (186)Re-1,1-hydroxyethylidene diphosphonate (etidronate) can be used for the palliative treatment of metastatic bone pain. A randomized, placebo-controlled study using (186)Re-etidronate was conducted on end-stage prostate cancer patients with metastatic bone pain. METHODS Pain relief was assessed using an electronic diary containing questions reflecting the multidimensional character of chronic pain. The diary was marked twice daily for a maximum of 14 wk (2 wk before and 12 wk… CONTINUE READING
37 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

Similar Papers

Loading similar papers…